

Prothromplex® TOTAL 500 IU - Implementation Checklist

Prothromplex® TOTAL 500 IU is indicated for:1

- Treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex coagulation factors, such as a deficiency caused by treatment with vitamin K antagonists or in case of overdose with vitamin K antagonists, when rapid correction of the deficiency is required.
- Treatment and perioperative prophylaxis of haemorrhages in congenital deficiency of vitamin K-dependent coagulation factors, when purified specific coagulation factor concentrate is not available.
- Prothromplex TOTAL 500 IU is indicated in adults. There are insufficient paediatric data to recommend the administration of Prothromplex TOTAL 500 IU in children.

Total annual volume allocation	
Potential cost efficiencies	

Subject/ considerations	Takeda support	Key action(s)	Responsibility / Lead	Timeframe	Status	Notes
Guidance/ Protocol updates	Guideline support document					
Formulary inclusion	Formulary pack					
Alloga - Ordering Account Set-up						
Laboratory Information Management System (LIMS) requirements						
Training requirements	Reconstitution guide Training video Dose calculator To access, once opened, click the download link to download the calculator to your local device					

Project team roles:

Role	Name					
Project Lead						
Lead Pharmacist						
Blood Bank Manager						
Transfusion Lead						
Haematologists						
Stroke Team						
Path Labs						
Comms						
Others						
This document has been developed as an aid in recording and managing the steps required to use Prothromplex® TOTAL 500 IU in your centre. You may also want to use it during calls with your Takeda contact to assess how things are progressing, and what further support might be required.						
Takeda contact:						
Completed by:		Scan or click this QR code to access Prothromplex® TOTAL 500 IU prescribing information				
Date:						
For mor	e information about Prothromplex® TOTAL 500 IU. please visit the Takeda Rare Disease Hub.					

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com

Alternatively, access this link: https://www.emcpi.com/pi/44073

References: 1. Prothromplex* TOTAL 500 IU. UK Summary of Product Characteristics.

© 2025 Takeda UK Limited. All rights reserved. Prothromplex* TOTAL 500 IU is a registered trademark of Baxalta Incorporated. Takeda* and the Takeda Logo* are registered trademarks of Takeda Pharmaceutical Company Limited.



